Cargando…
Tocilizumab for severe COVID-19 pneumonia
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431163/ https://www.ncbi.nlm.nih.gov/pubmed/32838327 http://dx.doi.org/10.1016/S2665-9913(20)30284-8 |
_version_ | 1783571539755532288 |
---|---|
author | Piano, Salvatore Vettor, Roberto Angeli, Paolo |
author_facet | Piano, Salvatore Vettor, Roberto Angeli, Paolo |
author_sort | Piano, Salvatore |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-7431163 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74311632020-08-18 Tocilizumab for severe COVID-19 pneumonia Piano, Salvatore Vettor, Roberto Angeli, Paolo Lancet Rheumatol Correspondence Elsevier Ltd. 2020-11 2020-08-17 /pmc/articles/PMC7431163/ /pubmed/32838327 http://dx.doi.org/10.1016/S2665-9913(20)30284-8 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Correspondence Piano, Salvatore Vettor, Roberto Angeli, Paolo Tocilizumab for severe COVID-19 pneumonia |
title | Tocilizumab for severe COVID-19 pneumonia |
title_full | Tocilizumab for severe COVID-19 pneumonia |
title_fullStr | Tocilizumab for severe COVID-19 pneumonia |
title_full_unstemmed | Tocilizumab for severe COVID-19 pneumonia |
title_short | Tocilizumab for severe COVID-19 pneumonia |
title_sort | tocilizumab for severe covid-19 pneumonia |
topic | Correspondence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431163/ https://www.ncbi.nlm.nih.gov/pubmed/32838327 http://dx.doi.org/10.1016/S2665-9913(20)30284-8 |
work_keys_str_mv | AT pianosalvatore tocilizumabforseverecovid19pneumonia AT vettorroberto tocilizumabforseverecovid19pneumonia AT angelipaolo tocilizumabforseverecovid19pneumonia AT tocilizumabforseverecovid19pneumonia |